Search

Genmab A-S

Закрыт

1,868.5 -1.71

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1864

Макс.

1907.5

Ключевые показатели

By Trading Economics

Доход

21M

52M

Продажи

-169M

896M

P/E

Средняя по отрасли

22.081

64.641

Прибыль на акцию

8.48

Рентабельность продаж

5.818

Сотрудники

3,088

EBITDA

-30M

215M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-1.49% downside

Дивиденды

By Acuity

Следующий отчет о доходах

6 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

12B

117B

Предыдущая цена открытия

1870.21

Предыдущая цена закрытия

1868.5

Genmab A-S График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

28 июл. 2026 г., 23:56 UTC

Correlated Moves

Shares of T Rowe Price Group Inc declined in after-market trading, reversing a trend of higher closes over the previous three sessions.

28 июл. 2026 г., 23:56 UTC

Krispy Kreme Inc shares are higher in after-market hours, reflecting broader market gains driven by strong earnings from Coca-Cola and UPS.

28 июл. 2026 г., 23:56 UTC

Northern Trust Corp shares are trading lower in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

28 июл. 2026 г., 23:56 UTC

Yelp Inc shares are higher in after-market hours, continuing a recent upward trend amid broader market gains driven by strong earnings from Coca-Cola and UPS.

28 июл. 2026 г., 23:56 UTC

Correlated Moves

ProPetro Holding Corp shares rose during after-market hours, aligning with a 3.61% increase in the VanEck Oil Services ETF amid positive sector sentiment.

28 июл. 2026 г., 23:56 UTC

Correlated Moves

Encore Capital Group shares rose in after-market hours, reflecting positive market sentiment. The Russell 2000 Index also increased, supporting investor confidence.

28 июл. 2026 г., 23:56 UTC

Immunovant Inc shares higher in after-market trading, reflecting broader market strength amid positive earnings from companies like UPS and Coca-Cola.

28 июл. 2026 г., 23:56 UTC

Palo Alto Networks shares rose in after-market trading, supported by broader market gains and strong earnings from companies like Coca-Cola and UPS.

28 июл. 2026 г., 23:56 UTC

Carvana Co shares are lower in after-market trading, with no specific news identified to explain the decline. The stock reversed from earlier gains.

28 июл. 2026 г., 23:56 UTC

Rollins Inc. shares rose slightly in after-market trading, with no specific news identified. Broader market gains were supported by strong earnings from UPS and Coca-Cola.

28 июл. 2026 г., 23:56 UTC

Viasat Inc. shares rose in after-market trading, reflecting broader market strength from positive earnings reports, including those from Coca-Cola and UPS.

28 июл. 2026 г., 23:56 UTC

News

Coursera Inc announced a $100 million investment in LearnVector, enhancing its AI strategy. Shares are trading higher during after-market hours.

28 июл. 2026 г., 23:56 UTC

Correlated Moves

Pentair PLC's shares were roughly flat in after-market hours amid broader market gains driven by strong earnings from Coca-Cola and UPS.

28 июл. 2026 г., 23:56 UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

28 июл. 2026 г., 23:56 UTC

Microchip Technology Inc shares are lower in after-market trading, continuing a six-session decline amid a broader market rally driven by strong earnings from UPS.

28 июл. 2026 г., 23:56 UTC

Correlated Moves

Vishay Intertechnology shares are lower in after-hours trading, continuing a decline seen since Tuesday. The stock remains below its 20-day moving average.

28 июл. 2026 г., 23:56 UTC

Viavi Solutions Inc shares are lower in after-market trading. No specific news was identified to explain the decline amid broader market gains.

28 июл. 2026 г., 23:56 UTC

Arista Networks Inc shares are lower in after-market hours. No specific news was identified for the decline, which follows three consecutive sessions of losses.

28 июл. 2026 г., 23:56 UTC

Geo Group Inc shares are higher in after-market hours, supported by broader market strength from strong earnings reports, including those from UPS and Coca-Cola.

28 июл. 2026 г., 23:56 UTC

Borgwarner Inc shares are higher in after-market trading, rebounding from an earlier dip amid broader market gains driven by strong earnings from UPS and Coca-Cola.

28 июл. 2026 г., 23:52 UTC

News
Correlated Moves
Social Media

Apple Inc. shares are higher in after-market trading as the company surpasses a $5 trillion market capitalization ahead of its Q3 earnings report.

28 июл. 2026 г., 23:52 UTC

OUTFRONT Media Inc shares are lower in after-market trading, declining since Tuesday's close despite three consecutive sessions of gains. No specific news was identified.

28 июл. 2026 г., 23:52 UTC

Mexican Consumer Confidence Index Set for Release Amid Global Mixed Signals and Local Pessimism, Anticipated to Reflect Economic Sentiment on August 4, 2026.

28 июл. 2026 г., 23:52 UTC

Brazil's Industrial Production MoM data for June 2026 set to release on August 4, amid cautious market sentiment following May's unexpected decline.

28 июл. 2026 г., 23:52 UTC

Brazil's Central Bank Faces Mixed Market Sentiment Ahead of August 2026 Interest Rate Decision Amid Inflation and Economic Concerns.

28 июл. 2026 г., 23:52 UTC

Australia's Producer Price Inflation (PPI) set for July 31, with a projected 0.3% increase amid cautious inflation sentiment and potential interest rate hikes from the Reserve Bank of Australia.

28 июл. 2026 г., 23:52 UTC

South Korea's S&P Global Manufacturing PMI set for August 3, with expectations of declining activity amid rising costs and significant stock market drops.

28 июл. 2026 г., 23:52 UTC

China's Non-Manufacturing PMI set for July 31 release, forecasted at neutral 50.0 amid mixed economic sentiment and geopolitical tensions.

28 июл. 2026 г., 23:52 UTC

China's NBS Manufacturing PMI forecasted to hold steady at 50.0, signaling stagnation amid mixed global manufacturing signals ahead of July 31st release.

28 июл. 2026 г., 23:52 UTC

Social Media
News

Avis Budget Group shares lower in after-market trading following second-quarter results that missed expectations, with EPS of $0.98 against estimates of $1.91.

Genmab A-S Прогноз

Целевая цена

By TipRanks

-1.49% падение

Прогноз на 12 месяцев

Средняя 2,493.35 DKK  -1.49%

Максимум 3,320 DKK

Минимум 308.417 DKK

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Genmab A-S на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

7 ratings

3

Покупка

2

Удержание

2

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat